1. Home
  2. NFE vs ACRS Comparison

NFE vs ACRS Comparison

Compare NFE & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo New Fortress Energy Inc.

NFE

New Fortress Energy Inc.

HOLD

Current Price

$0.50

Market Cap

324.4M

Sector

Utilities

ML Signal

HOLD

Logo Aclaris Therapeutics Inc.

ACRS

Aclaris Therapeutics Inc.

HOLD

Current Price

$4.37

Market Cap

311.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NFE
ACRS
Founded
2014
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Oil/Gas Transmission
Biotechnology: Pharmaceutical Preparations
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
324.4M
311.0M
IPO Year
2018
2015

Fundamental Metrics

Financial Performance
Metric
NFE
ACRS
Price
$0.50
$4.37
Analyst Decision
Buy
Strong Buy
Analyst Count
3
5
Target Price
$5.50
$10.20
AVG Volume (30 Days)
5.2M
1.2M
Earning Date
04-13-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
69.01
EPS
N/A
N/A
Revenue
$1,504,037,000.00
$1,683,000.00
Revenue This Year
$110.34
N/A
Revenue Next Year
$3.54
$4.24
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.50
$1.34
52 Week High
$4.96
$5.15

Technical Indicators

Market Signals
Indicator
NFE
ACRS
Relative Strength Index (RSI) 33.45 46.70
Support Level N/A $4.15
Resistance Level $0.77 $4.62
Average True Range (ATR) 0.05 0.22
MACD -0.01 -0.04
Stochastic Oscillator 1.74 25.00

Price Performance

Historical Comparison
NFE
ACRS

About NFE New Fortress Energy Inc.

New Fortress Energy Inc is an integrated gas-to-power company. Its business model spans the entire production and delivery chain from natural gas procurement and liquefaction to logistics, shipping, terminals, and conversion or development of a natural gas-fired generation. It has invested in floating, liquefied natural gas vessels to lower the cost of acquiring gas while securing a long-term supply for its terminals. Its segments include Terminals & Infrastructure, and Ships. It generates the majority of its revenue from the Terminals & Infrastructure segment.

About ACRS Aclaris Therapeutics Inc.

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.

Share on Social Networks: